Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
AAPM, AB, ACA, Alligator, Anatomic, antibiotic, antifungal, Apexigen, ASC, Barry, biomarker, Bioscience, blockade, BMS, Brook, Bulletin, burden, Calithera, Cantor, Century, check, CHIP, Clarifying, Coller, confronted, countermeasure, counterparty, cutoff, cytotoxic, dampen, Deputy, destroyed, destroying, disclaimed, durable, earliest, Efranat, Eli, enzyme, exit, fighting, Fitzgerald, flexibility, Forty, furniture, Gary, Gilliland, heal, hely, Hematopathology, insensitive, Jeffery, journal, Keystone, Kutok, lengthened, lieu, Lilly, Logix, macrophage, maker, mediated, modernize, move, neck, neurological, nivolumab, Nonretirement, notification, objective, occupy, Opdivo, OTC, overseen, patentee, pathobiology, pharmacodynamic, Pharmacokinetic, phenotype, PHSA, platelet, Plexxikon, Postemployment, poster, Prescriptoin, professor, quotation, ratio, Reauthorization, reauthorize, regenerative, repair, repeal, repealed, repealing, resistance, resistant, salary, Sawyer, SCCHN, Seattle, Secretary, session, Seth, shift, shutdown, solidify, spur, Stony, sublicense, Suffolk, Supplementary, suppression, Symposia, Tasker, threat, tissue, TME, top, Topic, Trailing, Trillium, Trump, twenty, unilaterally, unregistered, upregulation, Verastem, Vermont, voucher, week, world, wrong, XBiotech
Removed:
acid, acute, age, aggressive, Aileron, ALT, amide, anemia, antibody, applicability, arisen, ASH, AST, AstraZeneca, asymptomatic, bill, biochemistry, Boehringer, bone, borrowed, bortezomib, Bruton, BTK, cap, cellular, chemotherapy, CLL, CTCL, culture, custodian, deletion, diagnosed, diarrhea, differentiated, diffuse, disappointing, discontinued, discovering, DLBCL, dosed, drawn, DUOTM, entirety, equipped, evaluable, FAAH, facilitate, fatty, follicular, Forum, France, fundamentally, Genentech, Germany, Gilead, harmful, Hedgehog, hematologic, hydrochloride, hydrolase, ibrutinib, idelalisib, immunity, Ingelheim, inhibit, inInternal, initiating, intentionally, internally, investigated, Italy, JAK, Japan, jointly, Julian, kinase, Kingdom, LeukoSite, leverage, managing, mantle, marginal, marrow, mature, McGill, MCL, median, MedImmune, Merck, mg, migration, modification, monoclonal, mutation, mutually, neutropenia, NHL, ofatumumab, organic, outlook, paper, people, peripheral, Pharma, pharmacology, plc, poor, PPLP, progressed, progression, proliferation, proportion, ProScript, proteasome, PTCL, PTO, pursued, qualification, radioimmunotherapy, rash, relapsed, revised, Rhizen, rituximab, robust, ruxolitinib, SLL, Spain, stable, subtype, TG, topline, transient, tyrosine, understand, Velcade, zone
Filing tables
Filing exhibits
- 10-K Annual report
- 10.4 EX-10.4
- 10.13 EX-10.13
- 10.23 EX-10.23
- 10.24 EX-10.24
- 10.34 EX-10.34
- 10.35 EX-10.35
- 10.36 EX-10.36
- 10.37 EX-10.37
- 10.38 EX-10.38
- 10.39 EX-10.39
- 10.40 EX-10.40
- 21.1 EX-21.1
- 23.1 EX-23.1
- 31.1 EX-31.1
- 31.2 EX-31.2
- 32.1 EX-32.1
- 32.2 EX-32.2
- Download Excel data file
- View Excel data file
Related press release
INFIQ similar filings
Filing view
External links